Clinical Trial

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 2, 2024 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-10-29; most recent amendment 2024-11-27.
Status change: Not Yet Recruiting → Recruiting 2024-02-26
Trial Details
NCT Number NCT06112704
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Advanced Solid Tumor
Enrollment 220 participants
Start Date 2024-02-06
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-02